Ovarian Reserve Markers and Menstrual Pattern in Women Presenting with Primary Infertility
DOI:
https://doi.org/10.61919/rx964j57Keywords:
Primary infertility, ovarian reserve, anti-Müllerian hormone, antral follicle count, follicle-stimulating hormone, menstrual cycle, diminished ovarian reserve, PakistanAbstract
Background: Primary infertility requires timely evaluation of ovarian reserve, but advanced fertility testing may not be affordable or immediately available in resource-limited settings. Menstrual-cycle history is a simple clinical tool that may help identify women who require earlier ovarian reserve assessment. Objective: To assess the association between menstrual-cycle pattern and ovarian reserve markers among women presenting with primary infertility. Methods: This prospective observational study included 150 women with primary infertility attending a gynecology and infertility clinic in Islamabad, Pakistan. Menstrual-cycle pattern was categorized as regular, short, long, or irregular. Ovarian reserve was assessed using serum anti-Müllerian hormone, basal follicle-stimulating hormone, and antral follicle count. Diminished ovarian reserve was defined using predefined biochemical or ultrasound-based criteria. Group comparisons and crude secondary analyses were performed using the available aggregated data. Results: The mean age was 29.4 ± 4.8 years, mean infertility duration was 3.7 ± 2.1 years, and mean body mass index was 25.8 ± 3.9 kg/m². Diminished ovarian reserve was present in 36 women (24.0%). Women with short cycles had the lowest anti-Müllerian hormone (1.02 ± 0.71 ng/mL), lowest antral follicle count (5.6 ± 2.3 follicles), highest follicle-stimulating hormone (11.4 ± 3.9 IU/L), and highest frequency of diminished ovarian reserve (55.6%). Compared with regular cycles, short cycles showed higher crude odds of diminished ovarian reserve (OR 5.22, 95% CI 2.07–13.17). Conclusion: Short menstrual cycles were associated with an adverse ovarian reserve profile in women with primary infertility. Menstrual history may help prioritize early ovarian reserve testing but should not replace standard biochemical and ultrasound assessment
References
1. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151-1157. doi:10.1016/j.fertnstert.2020.09.134.
2. Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361-3373. doi:10.1210/clinem/dgaa513.
3. Dewailly D, Andersen CY, Balen A, Broekmans FJ, Dilaver N, Fanchin R, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update. 2014;20(3):370-385. doi:10.1093/humupd/dmt062.
4. Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129-140. doi:10.1016/j.ajog.2017.02.027.
5. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian hormone: above and beyond conventional ovarian reserve markers. Dis Markers. 2016;2016:5246217. doi:10.1155/2016/5246217.
6. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685-718. doi:10.1093/humupd/dml034.
7. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt PM, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26-36. doi:10.1093/humupd/dms041.
8. Harris BS, Steiner AZ, Jukic AM. Ovarian reserve biomarkers and menstrual cycle length in a prospective cohort study. J Clin Endocrinol Metab. 2021;106(9):e3748-e3759. doi:10.1210/clinem/dgab204.
9. Guzel Y, Aba YA, Yakin K, Oktem O. Menstrual cycle characteristics of young females with occult primary ovarian insufficiency at initial diagnosis and one-year follow-up with serum AMH level and antral follicle count. PLoS One. 2017;12(11):e0188334. doi:10.1371/journal.pone.0188334.
10. Sowers MF, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, et al. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril. 2010;94(4):1482-1486. doi:10.1016/j.fertnstert.2009.07.1674.
11. Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS, et al. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. J Clin Endocrinol Metab. 2012;97(10):E1871-E1879. doi:10.1210/jc.2012-1350.
12. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women’s health. Epidemiol Rev. 1995;17(2):265-286. doi:10.1093/oxfordjournals.epirev.a036193.
13. Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts R, et al. Anti-Müllerian hormone in the diagnosis of menstrual disturbance due to polycystic ovarian syndrome. Front Endocrinol. 2019;10:656. doi:10.3389/fendo.2019.00656.
14. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Müllerian hormone as a predictive marker in assisted reproductive technology. Hum Reprod Update. 2010;16(2):113-130. doi:10.1093/humupd/dmp036.
15. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-Müllerian hormone from conception to menopause. PLoS One. 2011;6(7):e22024. doi:10.1371/journal.pone.0022024.
16. Ferraretti AP, La Marca A, Fauser BCJM, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of poor response to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616-1624. doi:10.1093/humrep/der092.
17. Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065. doi:10.1093/hropen/hoae065.
18. Ali S, Sophie R, Imam AM, Khan FI, Ali SF, Shaikh A, et al. Knowledge, perceptions and myths regarding infertility among selected adult population in Pakistan: a cross-sectional study. BMC Public Health. 2011;11:760. doi:10.1186/1471-2458-11-760.
19. Ahmed HM, Khan M, Yasmin F, Jawaid H, Khalid H, Shigri A, et al. Awareness regarding causes of infertility among out-patients at a tertiary care hospital in Karachi, Pakistan. Cureus. 2020;12(4):e7685. doi:10.7759/cureus.7685.
20. Hussain S, Iqbal N, Noor A, Bibi S, Ghazal S, Zahid N. Psychiatric morbidity among women with infertility in Pakistan: a cross-sectional survey. BMJ Open. 2025;15(3):e087903. doi:10.1136/bmjopen-2024-087903.
21. Abbas S, Hayat A, Shabir R, Sharif MM, Iqbal A, Abbas R. Anti-Mullarian hormone as a diagnostic marker of polycystic ovary syndrome. Pak Armed Forces Med J. 2024;74(1):188-191. doi:10.51253/pafmj.v74i1.9166.
22. Rehmat L, Zaki S, Khan HN, Khan UI, Rehman R. Anti-Mullerian hormone gene polymorphism in polycystic ovary syndrome: a pilot study. Pak J Med Sci. 2025;41(9):2646-2651. doi:10.12669/pjms.41.9.12104.
23. Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118(5):2245-2250. doi:10.1542/peds.2006-2481.
24. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. Patients with low prognosis in ART: a Delphi consensus to improve clinical management and research. Reprod Biol Endocrinol. 2024;22:120. doi:10.1186/s12958-024-01291-x.
25. Aykanat G, Ertan B, Kalkan FT, Yildiz S, Unal S, Ozdemir O. Association between menstrual cycle length and ovarian reserve markers and stimulation response: a retrospective cohort study. BMC Womens Health. 2026;26:159. doi:10.1186/s12905-026-04391-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maryam Jamal, Maryam Hussain, Dr. Komal Tooba Aftab, Laiba Irfan, Aisha, Aqdas Gulzar (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
© The Authors. This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
.png)
